ASX:IBX Imagion Biosystems (IBX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Imagion Biosystems Stock (ASX:IBX) Get Imagion Biosystems alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10.77 million shsAverage VolumeN/AMarket CapitalizationA$3.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California. Read More Receive IBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imagion Biosystems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBX Stock News HeadlinesMagSense milestone moves Imagion closer to phase II breast cancer trialOctober 7, 2025 | msn.comImagion Biosystems Enhances Financial Position with New Share IssuanceSeptember 30, 2025 | tipranks.comOptions Pro Reveals His #1 Retirement Income TradeThe current market is creating a perfect setup for my favorite trading strategy — one that doesn’t rely on risky crypto or waiting months for AI stocks to move. I’ve outlined exactly how it works in a free guide called How To Master The Retirement Trade, showing how I target short-term trades designed to deliver faster results with less stress.October 16 at 2:00 AM | Base Camp Trading (Ad)Health Check: Imagion is crossing the t’s and dotting the i’s on crucial breast imaging trial submissionSeptember 24, 2025 | msn.comPitt Street Research sees upside in ‘undervalued’ Imagion, tips ASX minnow as takeover targetSeptember 11, 2025 | msn.comHealth Check: Truscreen’s diagnosis is for revenue growth and cash flow break evenSeptember 10, 2025 | msn.comStockTake: Imagion starts MagSense manufacturing ahead of breast cancer trialSeptember 7, 2025 | msn.comImagion Biosystems Advances HER2 Breast Cancer Imaging ProgramSeptember 7, 2025 | tipranks.comSee More Headlines IBX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Imagion Biosystems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imagion Biosystems investors own include EMCORE (EMKR), Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and VelocityShares 1x Long VSTOXX Futures ETN (EVIX). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:IBX CIKN/A Webwww.imagionbiosystems.com Phone855-564-5264FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$6.32 million Net Margins-265.26% Pretax MarginN/A Return on Equity139.43% Return on Assets-109.93% Debt Debt-to-Equity Ratio-60.49 Current Ratio0.09 Quick Ratio4.04 Sales & Book Value Annual SalesA$5.92 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.00 Book ValueA($0.16) per share Price / BookN/AMiscellaneous Outstanding Shares35,650,000Free FloatN/AMarket CapA$3.62 million OptionableNot Optionable Beta2.05 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (ASX:IBX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthFed vs. Trump - A War With American Wealth At Stake The Fed's defiance of Trump thickens the plot to contro...American Hartford Gold | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imagion Biosystems Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imagion Biosystems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
